Insider · CIK 0001678620
Eugene Bauer
Files at EVMN (Evommune, Inc.). First filing -, latest -.
In brief
Eugene Bauer files SEC Form 4 as officer and director at EVMN (Evommune, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Eugene Bauer has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | EVMN Evommune, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +51,117 | $0.00 | $0 | 51,117 | Apr 17, 2026 |
| Dec 8, 2025 | EVMN Evommune, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Dec 19, 2025 |
| Dec 9, 2025 | EVMN Evommune, Inc. | FTax withholding Common Stock | -1,478 | $17.84 | $26k | 270,818 | Dec 11, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Common Stock | +25,812 | - | - | 272,296 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series Seed Preferred Stockderivative | -206,355 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series B Preferred Stockderivative | -12,500 | - | - | 0 | Nov 12, 2025 |
Questions about Eugene Bauer
Answered from the filings on this page, as of the latest one.
Is Eugene Bauer buying or selling?
Eugene Bauer has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Eugene Bauer's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Eugene Bauer has 0.
Where does Eugene Bauer file Form 4?
Eugene Bauer has filed Form 4 at EVMN (Evommune, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.